Who Generates More Revenue? Gilead Sciences, Inc. or Travere Therapeutics, Inc.

Gilead's revenue dominance over Travere in biotech industry.

__timestampGilead Sciences, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 20142489000000028203205
Thursday, January 1, 20153263900000099892000
Friday, January 1, 201630390000000133591000
Sunday, January 1, 201726107000000154937000
Monday, January 1, 201822127000000164246000
Tuesday, January 1, 201922449000000175338000
Wednesday, January 1, 202024689000000198321000
Friday, January 1, 202127305000000227490000
Saturday, January 1, 202227281000000212018000
Sunday, January 1, 202327116000000145238000
Monday, January 1, 202428754000000
Loading chart...

Unleashing insights

Revenue Showdown: Gilead Sciences vs. Travere Therapeutics

In the competitive landscape of biotechnology, revenue generation is a key indicator of a company's market strength and innovation prowess. Over the past decade, Gilead Sciences, Inc. has consistently outperformed Travere Therapeutics, Inc. in terms of revenue. From 2014 to 2023, Gilead's revenue peaked in 2015, reaching nearly 33 billion dollars, while Travere's highest revenue was approximately 227 million dollars in 2021. This stark contrast highlights Gilead's dominance, with revenues often exceeding Travere's by over 100 times. Despite Travere's steady growth, Gilead's strategic advancements in pharmaceuticals have kept it at the forefront of the industry. As we look to the future, the question remains: can Travere close the gap, or will Gilead continue to lead the charge in biotech revenue generation?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025